Singleron Biotechnologies is an innovative and rapidly growing company providing complete solutions for single-cell sequencing technologies. To improve clinical diagnosis, drug development, and health management, Singleron brings breakthrough single-cell analysis techniques to clinicans and researchers. The company was incorporated in January 2018 and currently has offices, laboratories, and manufacturing facilities in Cologne, Germany, Nanjing and Suzhou in China, and New Haven, CT, USA.
Singleron has attracted a team of experts with diverse expertise. Currently, there are about 500 full-time employees in the company. The leadership team and key employees have long-year industry experience in multinational companies, including QIAGEN, Beckton Dickinson, Roche, Illumina, Siemens, TSMC, and Novogene. The technical team has extensive and diverse hands-on experience in single-cell analysis, genomics, microfluidic systems, bioinformatics, database construction, instrument design, and clinical product development.
Singleron obtained a worldwide exclusive IP license from Yale University for its uniquely designed microfluidic single-cell processing device, and has developed the GEXSCOPE® single cell system based on this microfluidic device. The GEXSCOPE® system offers a single-cell analysis format that is highly suitable for clinical applications by addressing typical challenges in the single-cell sequencing workflow, such as difficult sample transport, complicated procedure, and high cost. Since its incorporation, Singleron has quickly developed key proprietary technologies and methods on microfluidic system design, tissue processing, single-cell barcoding and amplification, data analysis algorithms, data mining, and database construction. Singleron applied for over 100 patents and has already been granted more than 50 patents and over 50 software copyrights. GEXSCOPE® Single Cell RNA reagents and consumables, which enable RNA-seq library construction from thousands of single cells in parallel, were successfully launched in January 2019 and the Singleron Matrix instrument was launched in June 2020. The company has already worked with over 500 prominent research institutes, hospitals, and pharmaceutical companies worldwide, to promote adoption of innovative single-cell analysis technologies in clinics and drug discovery.
E-mail:info@singleronbio.com
Phone (Germany) - General:+49 221 16824777
Phone (Germany) - Tech support: +49 221 57003425
Phone (APAC):+65 6990 5987
Copyright © 2023 Singleron Biotechnologies